News

FDA Approves Brexucabtagene Autoleucel CAR-T Therapy for R/R B-ALL

10/04/2021

On October 1, 2021, the FDA approved brexucabtagene autoleucel for the use in the treatment of adult patients with R/R B-ALL.

On October 1, 2021, the FDA...

10/04/2021

Oncology

News

FDA Approves Chemo Component for Treatment of Patients With ALL

07/02/2021

The FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a chemotherapy regimen to treat adults and young patients with ALL and lymphoblastic lymphoma.

The FDA approved asparaginase...

07/02/2021

Oncology

News

Blinatumomab Improves Survival in Young Patients With High-Risk B-ALL

04/29/2021

Blinatumomab leads to an improvement in event-free survival (EFS) when compared to consolidation chemotherapy in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), according to a study published in JAMA...

Blinatumomab leads to an...

04/29/2021

Oncology

News

Chemo-Induced Drug Resistance Mutations Cause Relapse in ALL

09/29/2020

According to findings from a study by Benshang Li, MD, and colleagues, chemo-induced mutagenesis may be the source for relapse-inducing drug resistance mutations in ALL.

According to findings from a...

09/29/2020

Oncology

News

No 5-Year Improvement in DFS With ITT vs IT MTX for CNS Prophylaxis in B-Cell ALL

08/17/2020

In a study of young patients with high- or standard-risk B-cell ALL, ITT as postinduction CNS prophylaxis did not improve DFS at 5 years over IT MTX.

In a study of young patients...

08/17/2020

Oncology

News

Front-Line Hyper-CVAD Plus Ofatumumab Safe, Effective for Ph-Negative B-Cell ALL

07/30/2020

The combination of hyper-CVAD plus ofatumumab is safe and active in adults with Ph-negative CD20-positive B-cell ALL, phase 2 study findings confirm.

The combination of hyper-CVAD...

07/30/2020

Oncology

News

Hyper-CMAD With Liposomal Vincristine Yields High Response Rates in Newly Diagnosed ALL

05/12/2020

In a phase 2 study of patients with newly diagnosed ALL, liposomal vincristine plus intensive chemo (hyper-CMAD) was safe and yielded high response and survival rates.

In a phase 2 study of patients...

05/12/2020

Oncology

News

Subclonal Mutations Predict Poor Outcomes After Relapse in ALL

04/03/2020

Although subclonal NT5C2 mutations are rapidly eradicated by relapse therapy, they can predict inferior outcomes in patients with ALL.

Although subclonal NT5C2...

04/03/2020

Oncology

News

Venetoclax–Chemo Combo Shows Promise in Relapsed/Refractory T-Cell ALL

03/05/2020

Adding venetoclax to chemotherapy yielded promising clinical efficacy in patients with relapsed/refractory T-cell ALL.

Adding venetoclax to...

03/05/2020

Oncology

News

Transplant After Inotuzumab Ozogamicin Therapy Improves Survival in Relapsed/Refractory ALL

05/17/2019

A long-term survival benefit was observed in patients with relapsed/refractory ALL who received no prior HSCT and proceeded to transplant directly after remission with inotuzumab ozogamicin.

A long-term survival benefit was...

05/17/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology